Pfizer Inc. (NYSE:PFE) Shares Purchased by Community Bank of Raymore

Community Bank of Raymore boosted its holdings in Pfizer Inc. (NYSE:PFE) by 11.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 53,810 shares of the biopharmaceutical company’s stock after purchasing an additional 5,700 shares during the quarter. Community Bank of Raymore’s holdings in Pfizer were worth $1,493,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. VisionPoint Advisory Group LLC increased its stake in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares during the last quarter. GoalVest Advisory LLC increased its stake in Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares during the last quarter. Creekmur Asset Management LLC acquired a new stake in Pfizer during the fourth quarter worth about $32,000. Tennessee Valley Asset Management Partners acquired a new stake in Pfizer during the fourth quarter worth about $36,000. Finally, DiNuzzo Private Wealth Inc. acquired a new stake in Pfizer during the fourth quarter worth about $37,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have commented on PFE shares. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday, June 17th. Finally, Morgan Stanley increased their target price on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Ten investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $35.86.

Pfizer Price Performance

NYSE:PFE traded down $0.19 during trading hours on Wednesday, reaching $27.80. 3,288,296 shares of the stock were exchanged, compared to its average volume of 33,452,832. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The firm has a 50 day simple moving average of $27.77 and a 200-day simple moving average of $27.69. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $37.80.

Pfizer (NYSE:PFE) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter last year, the business posted $1.23 EPS. Pfizer’s quarterly revenue was down 19.5% compared to the same quarter last year. On average, research analysts predict that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 14th. Shareholders of record on Friday, May 10th were issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.04%. The ex-dividend date was Thursday, May 9th. Pfizer’s dividend payout ratio is presently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.